This meta-analysis study provided new information to physicians regarding the difference of pneumonitis and pneumonia in cancer patients treated with ICIs, especially those with PD-1 and CTLA4 inhibitors. Here, PDCD1 is linked to susceptibility to pneumonia measurement.